Gynecological Devices Market Valuation to Reach US$ 20.19 Billion By 2033 | Astute Analytica

Chicago, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The global gynecological devices market was valued at US$ 10.18 billion in 2024 and is expected to reach US$ 20.19 billion by 2033, growing at a CAGR of 7.90% during the forecast period 2025–2033.

The global gynecological devices market is currently navigating a period of profound and accelerated transformation. This is not a gradual evolution but a dynamic surge, creating a landscape rich with opportunity for manufacturers, investors, and healthcare systems worldwide. A confluence of powerful drivers—including an unprecedented influx of venture capital into women’s health technology, the escalating prevalence of complex gynecological conditions, and a wave of disruptive technological advancements—is fueling this robust growth. The market is moving beyond incremental improvements toward fundamental shifts in diagnostics and therapeutics.

Free Report Sample Available for Immediate Download: https://www.astuteanalytica.com/request-sample/gynecological-devices-market

An exhaustive analysis of data reveals a compelling, multi-layered narrative of expansion. This in-depth market research report dissects nine critical segments, presenting meticulously researched, data-driven insights that collectively illuminate the immense and multifaceted opportunities materializing across the global gynecological devices market.

Key Finding in Gynecological Devices Market

Venture Capital Investment Ignites a Firestorm of Femtech and Gynecological Device Innovation

The financial landscape for women’s health has been transformed by a massive surge of venture capital, directly spurring innovation and growth in the gynecological devices market. Funding for femtech startups has exceeded US$5 billion since 2020, with US$1.2 billion deployed in 2024 alone. Broadening the view to all women’s health startups brings the 2024 total to US$2.6 billion, and, including all women-centric conditions, investment in the US and Europe reached nearly US$10.6 billion in 2024.

This is a truly global trend. In Europe, €339.4 million was invested across 47 femtech deals in 2024, and European femtechs had already attracted over €334 million in venture capital by March 2025. This capital empowers companies to launch breakthrough products, fueling a new wave of innovation. Recent examples include Future Family securing a US$400 million financing program in April 2025 and ByHeart raising US$72 million the same month for manufacturing expansion.

Significant 2025 investments underscore the diversity of innovation: Gesynta Pharma (US$29 million) and Conceivable Life Sciences (US$18 million) are advancing novel treatments, while Delfina (US$17 million), Twentyeight Health (US$10 million), and Teal Health (US$10 million) highlight the growing impact of AI-powered maternal health and accessible care. The funding cascade continues with Kegg (US$6.5 million), Egal (US$4 million), Fizimed (€4 million), Ema (US$3 million), Trellis Health (US$1.8 million), Raaz (US$1 million), Calla Lily (£1 million), Mabel (€600,000), Femble (€350,000), and AuraFem Health (US$200,000). The UNICEF Venture Fund further nurtures innovation, offering up to US$100,000 in equity-free funding for emerging economies, ensuring support at every level.

Addressing Uterine Fibroids Creates a Significant and Highly Costly Market Opportunity

Uterine fibroids represent a highly prevalent and economically significant condition, creating a vast and sustained demand for effective therapeutic solutions within the gynecological devices market. The sheer scale of this public health issue is immense. As of 2024, the estimated annual economic cost of uterine fibroids in the United States has escalated to an astonishing US$41.4 billion. A major component of this economic burden is productivity loss, with an estimated US$17.2 billion lost annually in the U.S. due to missed work and short-term disability. The patient population itself is expanding, with data showing that the number of women in the U.S. diagnosed with uterine fibroids increased by 10.6% between 2010 and 2022. This steady growth signals a consistently expanding patient base requiring treatment. The high out-of-pocket cost of traditional surgical interventions further amplifies the market need for innovative, less invasive, and more cost-effective devices.

Without insurance coverage, a myomectomy procedure can cost between US$11,000 and US$22,000, while a full hysterectomy ranges from US$9,600 to US$24,000. Alternative, device-centric treatments also carry substantial price tags, with uterine artery embolization costing between US$10,000 and US$15,000, and radiofrequency ablation ranging from US$8,900 to US$20,000. These costs exhibit significant geographic variability; for instance, a laparoscopic hysterectomy could cost approximately US$28,000 in Cleveland, Ohio, while the same procedure in Atlanta, Georgia, might be closer to US$19,000. This cost-prohibitive environment creates a powerful incentive for the adoption of new technologies in the gynecological devices market that can offer superior outcomes at a lower total cost of care.

Assisted Reproductive Technology Forges a Burgeoning and Profitable Niche Device Market

The increasing societal demand for fertility assistance, driven by trends such as delayed parenthood and rising infertility rates, is a potent force shaping a specialized and highly profitable segment of the gynecological devices market. The global demand for these services is immense, with approximately 2.5 million In-Vitro Fertilization (IVF) cycles now being performed annually across the world. This trend is particularly pronounced in the United States, where the number of IVF cycles performed in SART (Society for Assisted Reproductive Technology) member clinics surged from 389,993 in 2022 to 432,641 in 2023. These procedures directly resulted in the birth of 95,860 babies in the U.S. in 2023. Comprehensive data from 2021 shows that 238,126 patients in the U.S. initiated a total of 413,776 ART cycles, demonstrating the high volume of procedures.

The financial investment from patients is substantial and directly fuels demand for the sophisticated equipment, consumables, and diagnostic tools used in these delicate procedures. The average cost of a single IVF cycle in the U.S. ranges from US$12,000 to US$17,000, with some reports from the Department of Health and Human Services placing the potential cost between US$15,000 and US$20,000. This sustained, high-value patient expenditure ensures a robust and growing revenue stream for manufacturers of the specialized instruments essential to modern fertility treatment, making it a cornerstone of the modern gynecological devices market.

Robotic Surgery Revolutionizes Gynecological Procedures and Propels Advanced System Device Adoption

Minimally invasive robotic surgery has become the gold standard for many gynecological procedures, offering greater precision, shorter recovery times, and improved patient outcomes. This shift is driving rapid adoption of advanced robotic surgical systems, with the da Vinci system leading the market. In 2024 alone, 2,683,000 procedures were performed globally using da Vinci systems, reflecting exponential usage growth. Hardware sales surged as well, with 493 da Vinci surgical systems placed in healthcare facilities in Q4 2024, bringing full-year placements to 1,526. This expansion resulted in substantial financial gains: Intuitive Surgical reported US$2.41 billion in revenue for Q4 2024, up 25% from the previous year.

Recurring revenue in the gynecological devices market from proprietary instruments and accessories climbed to US$1.41 billion in Q4, while capital sales of the systems hit US$1.97 billion for the full year. The da Vinci system generally sells for US$0.7 million to US$3.1 million, signifying significant capital commitment from hospitals. By 2020, over 5,500 da Vinci systems were installed in U.S. hospitals, with more than 2,000 hospitals nationwide now utilizing robotic surgery systems. This robust infrastructure supports continued growth: the global gynecological surgery robot market reached approximately US$3.2 billion in 2024 and is poised for further expansion. The outlook is especially strong given that nearly 600,000 hysterectomies are performed in the U.S. every year, many ideal for robotic assistance.

Rising Prevalence of Pelvic and Endometrial Disorders Spurs Urgent Device Innovation

A growing awareness among both patients and clinicians regarding the diagnosis and treatment of widespread yet historically underdiagnosed conditions such as endometriosis and pelvic organ prolapse (POP) is opening new frontiers for the gynecological devices market. The addressable patient population is substantial and expanding. Projections indicate that the number of American women suffering from at least one pelvic floor disorder is set to increase to 43.8 million by the year 2050. More specifically, the number of women with POP in the U.S. is expected to climb to 4.9 million by 2050, while the global population of POP patients is projected to reach an enormous 156 million by 2036.

For endometriosis, a condition infamous for its diagnostic challenges, the average time from symptom onset to a definitive diagnosis is currently a staggering 8 years and 10 months. This diagnostic delay represents a critical unmet need and a clear opportunity for innovative diagnostic devices. Promising clinical research is underway to address these therapeutic gaps. A clinical trial involving 36 participants is evaluating a cannabidiol extract for endometriosis pain and is expected to conclude in December 2024, while another larger pain reduction trial with 102 participants is set to conclude in August 2024. Success in these trials could pave the way for new treatment paradigms supported by new devices.

At-Home Testing Empowers Consumers and Rapidly Expands the Diagnostic Device Market

A fundamental paradigm shift toward patient-centric care, emphasizing convenience, privacy, and empowerment, is fueling explosive growth in the at-home testing sector. This consumer-driven movement represents a critical expansion corridor for the diagnostic segment of the gynecological devices market. The market size reflects this rapid adoption; the global at-home testing market is estimated to reach a value of US$7,789.1 million in 2025, a healthy increase from its US$7,432.3 million valuation in 2024. The fertility testing sub-market is a particularly strong contributor to this growth, and it is estimated to be valued at US$672.9 million in 2025.

Long-term projections are even more bullish, with the global Ovulation Test Market projected to expand to US$4.04 billion by 2032. Similarly, the broader global Fertility Testing Devices Market, which was valued at US$702.59 million in 2023, is projected to surge to an impressive US$1,171.55 million by 2032. The distribution channels for these devices are also modernizing to meet consumer demand. The online pharmacy segment has emerged as the dominant channel, holding the largest share of the fertility testing devices market in 2023 at 41.12%. This trend opens up a powerful direct-to-consumer channel, reshaping marketing and logistics for the entire gynecological devices market.

Core Surgical and Diagnostic Device Advancements Enhance Overall Patient Care Efficacy

Relentless and continuous innovation in the design and function of core surgical and diagnostic instruments remains a fundamental pillar of growth for the gynecological devices market. These advancements directly translate into improved clinical efficacy, enhanced safety profiles, and better patient experiences. A landmark development occurred in 2025 when Kephera Diagnostics launched its EndomTest, which stands as the first commercially available non-invasive blood test for endometriosis in the United States. This represents a significant leap forward in diagnostics. Simultaneously, the regulatory environment is adapting to support and safeguard this innovation.

In November 2024, the Food and Drug Administration (FDA) announced a new communications pilot program specifically designed to enhance the medical device recall process, a program that explicitly includes obstetrics and gynecology devices. This heightened focus on safety is critical, as evidenced by an April 2024 recall of Boston Scientific's Obsidio Embolic device. A comprehensive review of high-risk recalls from 2002 through 2016 identified 7 distinct class I recall events that affected over 88,000 women's health medical devices. This history informs the current proactive regulatory stance, which ultimately fosters greater trust and ensures the long-term, sustainable health of the gynecological devices market.

Tailor This Report to Your Specific Business Needs: https://www.astuteanalytica.com/ask-for-customization/gynecological-devices-market

The Staggering Economic Burden of Gynecological Conditions Underscores Urgent Device Need

The immense economic weight imposed by common gynecological conditions on healthcare systems, employers, and patients provides a powerful and persuasive argument for the value proposition of effective and cost-efficient medical devices. The annual economic burden of uterine fibroids in the U.S. is a clear example, estimated to be as high as US$41.4 billion. A major driver of this staggering cost is the impact on workforce productivity, with lost wages due to fibroids costing American women approximately US$17.2 billion every year. The economic drain extends beyond fibroids.

The annual surgical costs in the U.S. for treating pelvic organ prolapse now exceed US$1.523 billion. These multi-billion-dollar figures create a compelling business case for payers and healthcare providers to aggressively invest in advanced gynecological devices. Devices that can reduce the need for expensive surgeries, shorten hospital stays, minimize recovery times, and mitigate long-term complications offer a clear and quantifiable return on investment. This powerful economic reality serves as a persistent and significant demand driver for the entire gynecological devices market.

Global Gynecological Devices Market Major Players:

• Karl Storz SE & Co. KG
• Hologic Inc.
• Boston Scientific Corporation
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• CONMED Corporation
• CooperSurgical Inc.
• Coloplast A/S
• Johnson & Johnson (Ethicon)
• Medtronic plc
• Olympus Corporation
• Stryker Corporation
• Richard Wolf GmbH
• Intuitive Surgical
• Teleflex Incorporated
• Minerva Surgical Inc.
• Lumenis Ltd.
• Other Prominent Players

Market Segmentation:

By Product 

• Surgical Devices
• Gynecological Imaging Devices
• Portable Tools

By End Use 

• Hospital & Clinics
• Ambulatory Surgery Centers (ASCs)

By Region

• North America
• Europe
• Asia Pacific
• Middle East
• Africa
• South America

Explore the Report Before You Buy – Book a Walkthrough: https://www.astuteanalytica.com/report-walkthrough/gynecological-devices-market

About Astute Analytica

Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.

With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.

Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: sales@astuteanalytica.com
Website: https://www.astuteanalytica.com/
Follow us on: LinkedIn | Twitter | YouTube